Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGFR-TKI in NSCLC with asymptomatic brain metastases
NCT02250846Phase 2Unknown
- Start
- Jan 2015
- Primary completion
- Jan 2016
01
Overview
Phase 2, open-label trial in non-small cell lung cancer (NSCLC) and brain metastases. Primary endpoint: Intracranial Progression-Free Survival at 20 months. Status: unknown.
02
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on NCT02250846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02250846.